| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00299988 Details | 2019-12-11 Interventional | 2 | 24 | Antibodies Immunoglobulins Immunoglobulins… Rho(D) Immune G… gamma-Globulins Alzheimer Disea… Alzheimer's Dis… | - The study was terminated due to the results from another phase III study with IVIG: PMC5409846, NCT00818662 | |||
| NCT02689219 Details | 2019-12-10 Interventional | 2 | 18 | Brentuximab Ved… Carcinoma, Embr… Neoplasms Neoplasms, Germ… Testicular Neop… Embryonal Carci… Germ Cell Tumor… Nonseminomatous… Testicular Canc… Testis Cancer | lack of funding/ benefit - | |||
| NCT02115386 Details | 2019-12-10 Interventional | 3 | 7 | Nilotinib Leukemia Leukemia, Myelo… Leukemia, Myelo… Philadelphia Po… | Study was terminated by Novartis - | |||
| NCT01218867 Details | 2019-12-10 Interventional | 1/2 | 24 | Aldesleukin Cyclophosphamid… Fludarabine Kidney Neoplasm… Melanoma Neoplasm Metast… Neoplasms Neoplasms, Seco… Metastatic Canc… Metastatic Mela… Renal Cancer | No objective responses were observed. - | |||
| NCT02434146 Details | 2019-12-09 Interventional | 1/2 | 3 | Oxymetazoline Phenylephrine Neoplasm Oral Mucosa Transplant-Rela… | A company in China has decided to license the product This study was closed prematurely due to decreased numbers of eligible subjects. The full target accrual number was not achieved, and no study conclusions could be made. | |||
| NCT01816048 Details | 2019-12-09 Interventional | 2 | 8 | Fluorides Listerine Sodium Fluoride Prostatic Neopl… Prostate Cancer | Study supporter (Takeda) ended study drug for prostate cancer; enrollment ended prematurely. - | |||
| NCT00985946 Details | 2019-12-09 Interventional | 2 | 15 | Panobinostat Neuroendocrine … | Study did not meet statistical requirements to continue. This study was terminated early because of the use of objective response rate as the primary outcome measure, which is a shortcoming of this study. | |||
| NCT03851263 Details | 2019-12-06 Interventional | 4 | 0 | Evolocumab Coronary Artery… | Admisnitrative issues - | |||
| NCT01797965 2012-003176-39 Details | 2019-12-04 Interventional | 3 | 1501 | Daclizumab Multiple Sclero… Multiple Sclero… Sclerosis Relapsing-Remit… | Study terminated because of differences in the participant population under study compared with
indicated Zinbryta use in most countries. - | |||
| NCT01258868 Details | 2019-12-03 Interventional | 1 | 44 | Celecoxib Esophageal Neop… Mesothelioma Mesothelioma, M… Sarcoma Thymoma Esophageal Canc… Lung Cancer Mesolthelioma Thoracic Sarcom… | - - | |||
| NCT02825342 Details | 2019-12-02 Interventional | 4 | 60 | Citalopram Proton Pump Inh… Chest Pain Infarction Myocardial Infa… Chest Pain Rule… | Primary endpoint was reached. - | |||
| NCT01157975 Details | 2019-12-02 Interventional | 2 | 0 | Pioglitazone Prednisone Hepatitis Hepatitis A Hepatitis C | Study was completed in another site - | |||
| NCT02527460 Details | 2019-11-29 Interventional | 1 | 1 | Interleukin 1 R… Communicable Di… Infections Nervous System … Neuroinflammato… HIV Infections Neurologic Diso… | - - | |||
| NCT01375556 Details | 2019-11-29 Interventional | 1 | 33 | Ethanol Alcoholism Genetics | - - | |||
| NCT00230490 Details | 2019-11-29 Interventional | 2 | - | Adefovir Pradefovir Hepatitis Hepatitis B Hepatitis B, Ch… | Adverse findings from nonclinical carcinogenicity studies. - | |||
| NCT03343067 Details | 2019-11-27 Interventional | 3 | 11 | Estradiol Norethindrone Norethindrone A… Endometriosis | The study was terminated early for business reasons, not for safety concerns. Due to early study termination at Treatment Month 6 with low subject enrollment, no clinically or statistically meaningful efficacy conclusions can be made. The study was terminated early for business reasons, not for safety concerns. | |||
| NCT03811418 2017-004749-25 Details | 2019-11-26 Interventional | 3 | 0 | Docetaxel Pertuzumab Trastuzumab Vinorelbine Breast Neoplasm… Advanced Breast… HER2-positive B… | Study approved with treatment regimen based on current guidelines. However, reimbursement of
IMP was not feasible. - | |||
| NCT02112045 Details | 2019-11-26 Interventional | 2 | 90 | Melphalan Multiple Myelom… Neoplasms, Plas… | Terminated due to results of interim analysis - | |||
| NCT00140140 Details | 2019-11-26 Interventional | 1/2 | 16 | Albumin-Bound P… Lenograstim Paclitaxel Trastuzumab Vinorelbine Breast Neoplasm… Stage IV (Metas… | Unable to determine the optimum tolerated dose - | |||
| NCT03335293 Details | 2019-11-25 Interventional | 4 | 0 | Epinephrine Epinephryl bora… Racepinephrine Cesarean Sectio… Pregnancy | Due to FDA constraints on the off label use of the medications we will not be able to conduct
this evaluation. - |